You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Non-vitamin K antagonist oral anticoagulants and infective endocarditis
  1. Daniel Caldeira1,2,
  2. Joaquim J Ferreira1,2,
  3. Fausto J Pinto3,
  4. João Costa1,2
  1. 1 Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal
  2. 2 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisboa, Portugal
  3. 3 Serviço de Cardiologia, Hospital Universitário de Santa Maria, CAML, Centro Cardiovascular da Universidade de Lisboa – CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
  1. Correspondence to Professor Daniel Caldeira, Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina da Universidade de Lisboa, Lisbon 1649-028, Portugal; dgcaldeira{at}hotmail.com

https://doi.org/10.1136/heartjnl-2018-313168

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor We read with great interest the Editorial by Erwin and Lung, which stated that in patients treated with oral anticoagulants and concomitant infective endocarditis, it is recommended to switch/bridge with heparin in the first 2 weeks to decrease the bleeding risk if cerebral embolism occurs, particularly in staphylococcal endocarditis.1 We recognise that the rate of embolic complications …

    View Full Text

    Footnotes

    • Contributors All authors contributed to the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JJF had speaker and consultant fees with GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, Abbott, Bial, Merck-Serono, Grunenthal and Merck Sharp and Dohme. FJP had consultant and speaker fees with Astra Zeneca, Bayer, Boehringer Ingelheim, and Daiichi Sankyo. DC and JC do not have any competing interests to disclose.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles